Merck & Co’s Keytruda obtains approval for NSCLC

Merck & Co.’s immunotherapy Keytruda has received the green light as a first-line treatment, in combination with chemotherapy, for metastatic non-squamous, non-small-cell lung cancer. The approval reflects the positive results from the Phase III KEYNOTE-189 clinical trial, testing the combination Keytruda-chemotherapy vs chemotherapy alone. Immunotherapy Opdivo, by direct competitor BMS, some days ago was approved by FDA for SCLC in patients already treated twice, but with no therapeutic benefit.

(Source: Merck)